115 related articles for article (PubMed ID: 11332988)
1. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.
Materna V; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):176-84. PubMed ID: 11332988
[TBL] [Abstract][Full Text] [Related]
2. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
[TBL] [Abstract][Full Text] [Related]
3. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
4. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
Kowalski P; Surowiak P; Lage H
Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
[TBL] [Abstract][Full Text] [Related]
5. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
Materna V; Stege A; Surowiak P; Priebsch A; Lage H
Biochem Biophys Res Commun; 2006 Sep; 348(1):153-7. PubMed ID: 16876126
[TBL] [Abstract][Full Text] [Related]
6. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
[TBL] [Abstract][Full Text] [Related]
9. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.
Kool M; de Haas M; Scheffer GL; Scheper RJ; van Eijk MJ; Juijn JA; Baas F; Borst P
Cancer Res; 1997 Aug; 57(16):3537-47. PubMed ID: 9270026
[TBL] [Abstract][Full Text] [Related]
10. A structural analysis of in vitro catalytic activities of hammerhead ribozymes.
Shao Y; Wu S; Chan CY; Klapper JR; Schneider E; Ding Y
BMC Bioinformatics; 2007 Nov; 8():469. PubMed ID: 18053134
[TBL] [Abstract][Full Text] [Related]
11. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells.
Narasaki F; Oka M; Nakano R; Ikeda K; Fukuda M; Nakamura T; Soda H; Nakagawa M; Kuwano M; Kohno S
Biochem Biophys Res Commun; 1997 Nov; 240(3):606-11. PubMed ID: 9398612
[TBL] [Abstract][Full Text] [Related]
12. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.
Kobayashi H; Dorai T; Holland JF; Ohnuma T
Cancer Res; 1994 Mar; 54(5):1271-5. PubMed ID: 8118816
[TBL] [Abstract][Full Text] [Related]
13. Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.
Oguri T; Fujiwara Y; Isobe T; Katoh O; Watanabe H; Yamakido M
Br J Cancer; 1998 Apr; 77(7):1089-96. PubMed ID: 9569044
[TBL] [Abstract][Full Text] [Related]
14. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins.
Iida T; Kijima H; Urata Y; Goto S; Ihara Y; Oka M; Kohno S; Scanlon KJ; Kondo T
Cancer Gene Ther; 2001 Oct; 8(10):803-14. PubMed ID: 11687904
[TBL] [Abstract][Full Text] [Related]
15. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA.
Palfner K; Kneba M; Hiddemann W; Bertram J
Biol Chem Hoppe Seyler; 1995 May; 376(5):289-95. PubMed ID: 7544982
[TBL] [Abstract][Full Text] [Related]
16. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins.
Belinsky MG; Bain LJ; Balsara BB; Testa JR; Kruh GD
J Natl Cancer Inst; 1998 Nov; 90(22):1735-41. PubMed ID: 9827529
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms for resistance to anticancer agents and the reversal of the resistance].
Akiyama S; Chen ZS; Kitazono M; Sumizawa T; Furukawa T; Aikou T
Hum Cell; 1999 Sep; 12(3):95-102. PubMed ID: 10695015
[TBL] [Abstract][Full Text] [Related]
18. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2).
Kawabe T; Chen ZS; Wada M; Uchiumi T; Ono M; Akiyama S; Kuwano M
FEBS Lett; 1999 Aug; 456(2):327-31. PubMed ID: 10456333
[TBL] [Abstract][Full Text] [Related]
19. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Borst P; Kool M; Evers R
Semin Cancer Biol; 1997 Jun; 8(3):205-13. PubMed ID: 9441949
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA.
De Young MB; Kincade-Denker J; Boehm CA; Riek RP; Mamone JA; McSwiggen JA; Graham RM
Biochemistry; 1994 Oct; 33(40):12127-38. PubMed ID: 7918434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
